AngioDynamics(US:ANGO)2022-04-04 19:10Financial Performance - AngioDynamics' Q2 FY2022 revenue increased by 76% to $78280 thousand compared to $72770 thousand in Q2 FY2021[31] - Year-to-date FY2022 revenue increased by 86% to $155251 thousand compared to $142986 thousand in YTD FY2021[31] - Gross margin for Q2 FY2022 was 518%, a decrease of 340 bps compared to 552% in Q2 FY2021[31] - The net loss for Q2 FY2022 was $8351 thousand, compared to a net loss of $4268 thousand in Q2 FY2021[31] - Adjusted EPS for Q2 FY2022 was ($002), compared to $001 in Q2 FY2021[31] - Adjusted EBITDA for Q2 FY2022 was $4421 thousand, compared to $5158 thousand in Q2 FY2021[31] Revenue Contribution and Growth - Med Tech revenue contribution in Q2 FY22 was 24% and Med Device was 76%[32] - Med Tech revenue contribution YTD FY22 was 24% and Med Device was 76%[32] - Med Tech revenue grew by 364% in Q2 FY22 and 500% YTD FY22[32] Thrombus Management - The total addressable market (TAM) for Deep Vein Thrombosis in 2020 was $13 billion[8] - The total addressable market (TAM) for Pulmonary Embolism in 2020 was $16 billion[8]